Christophe Weber, Takeda CEO (Shoko Takayasu/Bloomberg via Getty Images)
September 21, 2022 07:40 AM EDT
R&D

Take­da punts dis­ap­point­ing late-stage Mil­len­ni­um drug for $7M in cash

Amber Tong

Take­da has man­aged to of­fload an ex­per­i­men­tal can­cer drug that’s been sit­ting on the shelf — in ex­change for $7 mil­lion in cash plus mile­stones. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times